Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

Lung cancer is the most common neoplastic disease globally, with over 2 million new cases annually, accounting for 11.6% of all cancer diagnoses. It remains the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) makes up 80-85% of lung cancer cases, with most patients diagnosed at an advanced stage. Five-year survival rates are low, ranging from 8-18% worldwide. Advances in molecular biology have led to the identification of therapeutic targets in NSCLC. One of the most studied is the epidermal growth factor receptor (EGFR), a key regulator of tumor cell functions and

Trial Details

NCT ID

NCT05445791

Phase

PHASE3

Sponsor

Instituto Nacional de Cancerologia de Mexico

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Metformin Hydrochloride
Placebo

Locations (sample)

Mexico City, Mexico|19.42847,-99.12766

Key Eligibility Criteria

Patients with a histologically confirmed diagnosis of non-small cell lung cancer (stage IIIB-IV) according to the American Joint Committee on Cance…
Measurable disease by RECIST 1.1.
18 years of age or older.
Functional status 0-2 as assessed by Eastern Cooperative Oncology Group (ECOG) scale.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →